



## Exparel® (bupivacaine) – Expanded indication

- On March 22, 2021, [Pacira BioSciences announced](#) the FDA approval of [Exparel \(bupivacaine\)](#), in patients aged 6 years and older for single-dose infiltration to produce postsurgical local analgesia.
  - Exparel was previously approved for this indication in adults only.
- Exparel is also approved in adults as an interscalene brachial plexus nerve block to produce postsurgical regional analgesia.
- The approval of Exparel for the expanded indication was based on a randomized, open-label study evaluating the pharmacokinetics and safety of Exparel in 95 pediatric patients aged 6 to less than 17 years who were undergoing spine or cardiac surgery. The efficacy of Exparel for local infiltration for pediatric patients (6 to less than 17 years of age) was extrapolated from the efficacy of Exparel for local infiltration for adults.
- The most common adverse reactions ( $\geq 10\%$ ) with Exparel use in pediatric patients six to less than 17 years of age were nausea, vomiting, constipation, hypotension, anemia, muscle twitching, blurred vision, pruritis, and tachycardia.
- The recommended dose of Exparel in pediatric patients is 4 mg/kg (up to a maximum of 266 mg) as a single-dose infiltration. The dose is based upon two studies of pediatric patients undergoing either spine surgery or cardiac surgery.
  - Refer to the Exparel drug label for dosing in adults and for complete injection instructions.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.